ArriVent BioPharma, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Zhengbin Yao
- Full Time Employees
- 52
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 18 Campus Boulevard Newtown Square United States of America 19073
- IPO Date
- Jan 26, 2024
- CIK
- 0001868279
- Website
- arrivent.com
- Similar Companies
- Business
- ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on developing precision therapies targeting genetically defined oncology indications. The company advances a pipeline of novel product candidates, including furmonertinib, a highly selective EGFR inhibitor for EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC); telaglenastat, a glutaminase inhibitor combined with everolimus for renal cell carcinoma; and ARV-393, a RAG1/RAG2-targeted degrader for solid tumors. It offers research and development services in targeted oncology, emphasizing biomarker-driven approaches and companion diagnostics; preclinical and clinical trial management; and regulatory support for oncology therapeutics. ArriVent operates primarily in the United States and China, targeting patients with specific genetic mutations in lung, kidney, and other cancers through partnerships with academic institutions and healthcare providers. Founded in 2019 and headquartered in Waltham, Massachusetts, the company maintains a subsidiary structure for international operations, with no parent company affiliation. In recent developments, ArriVent completed a business combination with a special purpose acquisition company in 2023, enabling its public listing on Nasdaq; secured a strategic collaboration with Johnson & Johnson Innovative Medicine in 2024 to co-develop furmonertinib globally, including a potential $1 billion in milestone payments; initiated Phase 3 trials for furmonertinib in frontline EGFR mutant NSCLC; and raised $150 million in a follow-on equity offering in mid-2025 to fund pipeline expansion.
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
ArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
ArriVent BioPharma Reports Full Year 2025 Financial Results
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Moderate Buy” by Analysts
Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
$207B Market Shift: The Race for Fast Track Approval in Oncology
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
12,735 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by AXQ Capital LP
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts